vimarsana.com
Home
Live Updates
LQT Therapeutics Announces Award by the European Joint Program for Rare Diseases for SGK1 inhibition as a novel therapeutic approach in Long QT syndrome : comparemela.com
LQT Therapeutics Announces Award by the European Joint Program for Rare Diseases for SGK1 inhibition as a novel therapeutic approach in Long QT syndrome
/PRNewswire/ - LQT Therapeutics, a privately-held biopharmaceutical company advancing novel SGK1 kinase therapeutics, today announced that the project...
Related Keywords
Amsterdam ,
Noord Holland ,
Netherlands ,
Debra Odink ,
Arthur Wilde ,
Therapeutics Inc ,
Amsterdam University Medical Centers ,
Ejp Rd Consortium Member ,
European Joint Program On Rare Diseases ,
Joint Program ,
Rare Diseases ,
Congenital Long ,
Chief Development Officer ,
Lqt Therapeutics Inc ,
comparemela.com © 2020. All Rights Reserved.